EvergreenHealth

evergreenhealth.com

EvergreenHealth, a public hospital district, is an integrated health care system offering a breadth of services and programs that is among the most comprehensive in the region. In addition to the 318-bed acute care hospital on EvergreenHealth’s main campus in Kirkland, which includes 24-hour Level III trauma emergency care and critical care, EvergreenHealth provides primary, urgent, and specialty care along with a 24/7 emergency department at its satellite EvergreenHealth Redmond Medical Center.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

FSD PHARMA ANNOUNCES LAUNCH OF NEW CORPORATE WEBSITE

FSD Pharma Inc. | January 24, 2022

news image

FSD Pharma Inc. a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today the launch of its newly designed website. The new site conveys the Company’s emerging position within the biopharmaceutical industry and its ongoing commitment to bring novel treatment solutions for brain and inflammatory disorders to millions of patients in need. “We have strategically assembled a team of scient...

Read More

Pharmacy Market

KARYOPHARM RECEIVES FDA FAST TRACK DESIGNATION FOR SELINEXOR FOR THE TREATMENT OF MYELOFIBROSIS

PRNewswire | July 18, 2023

news image

Karyopharm Therapeutics Inc. a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to the development program of selinexor for the treatment of patients with myelofibrosis, including primary myelofibrosis, post-essential thrombocythemia myelofibrosis, and post-polycythemia vera myelofibrosis. "Fast Track Designation for selinexor highlights its...

Read More

Pharmacy Market

PAN-TB COLLABORATION ANNOUNCES THE START OF A PHASE 2 CLINICAL TRIAL TO EVALUATE TWO NOVEL TUBERCULOSIS TREATMENT REGIMENS

PRNewswire | August 10, 2023

news image

The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) collaboration announced today the start of a phase 2b/c clinical trial, sponsored by the Bill & Melinda Gates Medical Research Institute (Gates MRI). The trial will evaluate whether novel regimens that combine registered products and new chemical entities have the potential to effectively treat drug-sensitive TB (DS-TB) and inform the development of a "pan-TB" regimen capable of treating all forms of active pu...

Read More

Business Insights

ERS GENOMICS AND LEPTON PHARMACEUTICALS LTD ENTER CRISPR/CAS9 LICENSE AGREEMENT

ERS Genomics | July 27, 2022

news image

ERS Genomics Limited is pleased to announce a new license agreement with Lepton Pharmaceuticals LTD. This is a non-exclusive licensing agreement granting Lepton access to the ERS CRISPR/Cas9 patent portfolio for certain applications. ERS, co-founded by Dr. Emmanuelle Charpentier, 2020 Nobel Prize winner for gene-editing, provides access to the foundational CRISPR/Cas9 intellectual property. Over 90 patents are held in over eighty countries. Lepton Pharmaceutical LTD...

Read More
news image

Business Insights

FSD PHARMA ANNOUNCES LAUNCH OF NEW CORPORATE WEBSITE

FSD Pharma Inc. | January 24, 2022

FSD Pharma Inc. a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today the launch of its newly designed website. The new site conveys the Company’s emerging position within the biopharmaceutical industry and its ongoing commitment to bring novel treatment solutions for brain and inflammatory disorders to millions of patients in need. “We have strategically assembled a team of scient...

Read More
news image

Pharmacy Market

KARYOPHARM RECEIVES FDA FAST TRACK DESIGNATION FOR SELINEXOR FOR THE TREATMENT OF MYELOFIBROSIS

PRNewswire | July 18, 2023

Karyopharm Therapeutics Inc. a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to the development program of selinexor for the treatment of patients with myelofibrosis, including primary myelofibrosis, post-essential thrombocythemia myelofibrosis, and post-polycythemia vera myelofibrosis. "Fast Track Designation for selinexor highlights its...

Read More
news image

Pharmacy Market

PAN-TB COLLABORATION ANNOUNCES THE START OF A PHASE 2 CLINICAL TRIAL TO EVALUATE TWO NOVEL TUBERCULOSIS TREATMENT REGIMENS

PRNewswire | August 10, 2023

The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) collaboration announced today the start of a phase 2b/c clinical trial, sponsored by the Bill & Melinda Gates Medical Research Institute (Gates MRI). The trial will evaluate whether novel regimens that combine registered products and new chemical entities have the potential to effectively treat drug-sensitive TB (DS-TB) and inform the development of a "pan-TB" regimen capable of treating all forms of active pu...

Read More
news image

Business Insights

ERS GENOMICS AND LEPTON PHARMACEUTICALS LTD ENTER CRISPR/CAS9 LICENSE AGREEMENT

ERS Genomics | July 27, 2022

ERS Genomics Limited is pleased to announce a new license agreement with Lepton Pharmaceuticals LTD. This is a non-exclusive licensing agreement granting Lepton access to the ERS CRISPR/Cas9 patent portfolio for certain applications. ERS, co-founded by Dr. Emmanuelle Charpentier, 2020 Nobel Prize winner for gene-editing, provides access to the foundational CRISPR/Cas9 intellectual property. Over 90 patents are held in over eighty countries. Lepton Pharmaceutical LTD...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us